BridgeBio Pharma (BBIO) Financials

$33.34 +0.37 (+1.12%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$34.65 +1.31 (+3.93%)

As of 05/23/2025 07:48 PM Eastern

Annual Income Statements for BridgeBio Pharma

This table shows BridgeBio Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Income / (Loss) Attributable to Common Shareholders	-536	-643	-481	-563	-449	-261	-131	-31
Consolidated Net Income / (Loss)	-543	-653	-485	-586	-505	-289	-169	-44
Net Income / (Loss) Continuing Operations	-543	-653	-485	-586	-505	-289	-169	-44
Total Pre-Tax Income	-542	-653	-485	-586	-505	-289	-169	-44
Total Operating Income	-593	-607	-512	-577	-474	-266	-184	-44
Total Gross Profit	218	6.86	74	67	8.25	41	0.00	0.00
Total Revenue	222	9.30	78	70	8.25	41	0.00	0.00
Operating Revenue	222	9.30	78	70	8.25	41	0.00	0.00
Total Cost of Revenue	3.88	2.45	3.43	3.11	0.00	0.00	0.00	0.00
Operating Cost of Revenue	3.88	2.45	3.43	3.11	-	0.00	-	-
Total Operating Expenses	811	614	586	643	483	307	184	44
Selling, General & Admin Expense	289	151	143	192	146	94	44	13
Research & Development Expense	506	456	399	451	337	210	140	31
Restructuring Charge	16	7.93	44	0.00	0.00	-	-	-
Total Other Income / (Expense), net	51	-46	28	-9.82	-31	-22	14	0.03
Interest Expense	126	81	80	47	37	8.77	2.55	0.01
Interest & Investment Income	164	18	7.54	1.13	4.02	-12	21	0.04
Other Income / (Expense), net	12	17	100	36	1.63	-1.63	-4.30	0.00
Income Tax Expense	1.15	0.00	0.00	-	-	-	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	-7.59	-10	-3.47	-24	-57	-28	-39	-13
Basic Earnings per Share	($2.88)	($3.95)	($3.26)	($3.90)	($3.80)	($2.48)	($2.12)	($1.00)
Weighted Average Basic Shares Outstanding	186.08M	162.79M	147.47M	144.36M	118.00M	105.10M	61.77M	30.60M
Diluted Earnings per Share	($2.88)	($3.95)	($3.26)	($3.90)	($3.80)	($2.48)	($2.12)	($1.00)
Weighted Average Diluted Shares Outstanding	186.08M	162.79M	147.47M	144.36M	118.00M	105.10M	61.77M	30.60M
Weighted Average Basic & Diluted Shares Outstanding	190.19M	175.83M	151.37M	144.36M	118.00M	105.10M	61.77M	30.60M

This table shows BridgeBio Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-167	-265	-162	-73	-35	-168	-177	-158	-140	-138	-137
Consolidated Net Income / (Loss)	-170	-267	-164	-76	-36	-170	-179	-161	-143	-141	-140
Net Income / (Loss) Continuing Operations	-170	-267	-164	-76	-36	-170	-179	-161	-143	-141	-140
Total Pre-Tax Income	-170	-266	-164	-76	-36	-170	-179	-161	-143	-141	-140
Total Operating Income	-104	-226	-192	-176	0.34	-177	-158	-146	-126	-129	-129
Total Gross Profit	114	3.80	2.13	1.57	211	1.15	3.49	1.04	1.18	-0.13	-0.40
Total Revenue	117	5.88	2.73	2.17	211	1.75	4.09	1.64	1.83	1.87	0.34
Operating Revenue	117	5.88	2.73	2.17	211	1.75	4.09	1.64	1.83	1.87	0.34
Total Cost of Revenue	2.64	2.08	0.60	0.60	0.60	0.60	0.60	0.60	0.65	2.00	0.74
Operating Cost of Revenue	2.64	2.08	0.60	0.60	0.60	0.60	0.60	0.60	0.65	-	0.74
Total Operating Expenses	218	230	194	177	210	179	161	147	127	130	129
Selling, General & Admin Expense	106	95	69	60	66	48	36	36	31	32	31
Research & Development Expense	111	130	120	115	141	130	125	107	93	91	93
Restructuring Charge	0.57	4.69	4.62	2.89	3.40	0.75	0.27	3.53	3.37	7.69	5.02
Total Other Income / (Expense), net	-65	-40	27	100	-37	7.09	-22	-15	-17	-11	-11
Interest Expense	63	30	23	23	50	20	20	21	20	20	20
Interest & Investment Income	-10	-12	49	124	4.08	5.58	3.79	4.51	4.15	4.09	2.42
Other Income / (Expense), net	8.23	1.62	1.80	-0.63	9.48	22	-5.28	1.48	-0.60	4.56	6.33
Net Income / (Loss) Attributable to Noncontrolling Interest	-2.19	-2.34	-2.21	-2.09	-0.94	-2.18	-2.49	-2.80	-2.58	-2.98	-2.85
Basic Earnings per Share	($0.88)	($1.43)	($0.86)	($0.39)	($0.20)	($0.97)	($1.08)	($0.98)	($0.92)	($0.91)	($0.93)
Weighted Average Basic Shares Outstanding	190.15M	186.08M	188.51M	187.59M	178.71M	162.79M	163.31M	160.54M	152.65M	147.47M	147.94M
Diluted Earnings per Share	($0.88)	($1.43)	($0.86)	($0.39)	($0.20)	($0.97)	($1.08)	($0.98)	($0.92)	($0.91)	($0.93)
Weighted Average Diluted Shares Outstanding	190.15M	186.08M	188.51M	187.59M	178.71M	162.79M	163.31M	160.54M	152.65M	147.47M	147.94M
Weighted Average Basic & Diluted Shares Outstanding	189.88M	190.19M	188.99M	188.03M	187.13M	175.83M	173.97M	162.47M	160.50M	151.37M	149.48M

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Change in Cash & Equivalents	289	-22	21	38	-5.52	-72	344	72
Net Cash From Operating Activities	-521	-528	-419	-498	-400	-254	-137	-40
Net Cash From Continuing Operating Activities	-521	-528	-419	-498	-400	-254	-137	-40
Net Income / (Loss) Continuing Operations	-543	-653	-485	-586	-505	-289	-169	-44
Consolidated Net Income / (Loss)	-543	-653	-485	-586	-505	-289	-169	-44
Depreciation Expense	6.08	6.49	6.77	5.84	1.46	0.86	-	-
Non-Cash Adjustments To Reconcile Net Income	-15	114	30	61	86	45	10	2.10
Changes in Operating Assets and Liabilities, net	32	5.06	28	21	18	-11	22	1.24
Net Cash From Investing Activities	61	54	453	-201	-53	-217	-21	-0.46
Net Cash From Continuing Investing Activities	61	54	453	-201	-53	-217	-21	-0.46
Purchase of Property, Plant & Equipment	-0.93	-1.31	-4.82	-13	-7.52	-2.64	-2.18	-0.46
Acquisitions	-7.98	0.00	-1.50	-35	0.00	0.00	-16	0.00
Purchase of Investments	-114	-137	-193	-643	-288	-213	0.00	0.00
Sale of Property, Plant & Equipment	0.00	0.00	10	0.00	0.00	-	0.00	-
Sale and/or Maturity of Investments	184	193	533	477	249	0.00	0.00	-
Other Investing Activities, net	-0.14	-0.50	110	14	-6.76	-1.72	0.00	-
Net Cash From Financing Activities	748	452	-13	736	447	399	502	113
Net Cash From Continuing Financing Activities	748	452	-13	733	447	397	502	113
Repayment of Debt	-489	0.00	-20	-140	-13	-0.82	55	0.13
Issuance of Debt	450	0.00	0.00	1,204	550	37	1.00	4.00
Issuance of Common Equity	319	453	7.41	3.82	25	391	96	0.00
Other Financing Activities, net	469	-1.67	-0.90	-49	-35	25	59	2.98
Cash Interest Paid	91	61	54	30	15	6.09	1.57	0.00

This table details how cash moves in and out of BridgeBio Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-141	275	-142	72	83	-129	199	-110	18	-69	13
Net Cash From Operating Activities	-199	-195	-181	75	-220	-125	-145	-113	-144	-93	-135
Net Cash From Continuing Operating Activities	-199	-195	-181	75	-220	-125	-145	-113	-144	-93	-135
Net Income / (Loss) Continuing Operations	-170	-267	-164	-76	-36	-170	-179	-161	-143	-141	-140
Consolidated Net Income / (Loss)	-170	-267	-164	-76	-36	-170	-179	-161	-143	-141	-140
Depreciation Expense	1.28	1.37	1.54	1.57	1.60	1.59	1.64	1.64	1.63	1.66	1.65
Non-Cash Adjustments To Reconcile Net Income	85	56	-16	137	-194	10	35	34	35	40	4.96
Changes in Operating Assets and Liabilities, net	-116	14	-2.32	12	8.54	34	-2.13	11	-38	6.10	-1.58
Net Cash From Investing Activities	-1.60	-3.24	38	3.04	23	-0.07	38	4.12	12	18	147
Net Cash From Continuing Investing Activities	-1.60	-3.24	38	3.04	23	-0.07	38	4.12	12	18	147
Purchase of Property, Plant & Equipment	0.00	-0.05	-0.14	-0.05	-0.70	-0.44	-0.43	-0.43	-0.01	-0.80	-0.76
Acquisitions	-1.60	-3.19	-1.60	-2.39	-0.80	-	-	-	0.00	-	-
Purchase of Investments	0.00	-	-	-49	-65	-29	-17	-44	-47	-32	-30
Sale and/or Maturity of Investments	0.00	-	40	55	89	30	55	48	60	51	178
Net Cash From Financing Activities	60	474	0.71	-5.73	280	-4.52	307	-1.23	150	6.38	1.45
Net Cash From Continuing Financing Activities	60	474	0.71	-5.73	280	-4.52	307	-1.23	150	6.38	1.45
Repayment of Debt	-471	-	-	-3.73	-486	-	-4.56	-1.18	5.74	1.96	-
Repurchase of Common Equity	-48	-	-	-	-	-	-	-	-	-	-
Issuance of Debt	575	-	-	-	450	-	-	-	0.00	-	-
Issuance of Common Equity	3.24	-	2.12	-0.50	318	-0.45	308	1.03	145	4.85	1.59
Other Financing Activities, net	1.55	474	-1.41	-1.50	-2.40	-4.07	3.80	-1.08	-0.32	-0.43	-0.15
Cash Interest Paid	23	13	29	14	35	10	22	6.68	22	6.87	22

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Assets	919	546	623	1,013	704	632	465
Total Current Assets	721	478	549	889	643	569	445
Cash & Equivalents	681	376	377	394	356	364	436
Restricted Cash	0.13	17	38	0.18	-	-	-
Short-Term Investments	0.00	59	95	443	251	182	0.00
Note & Lease Receivable	0.00	0.00	17	20	-	-	-
Accounts Receivable	4.72	1.75	-	-	-	2.85	-
Prepaid Expenses	35	24	22	32	36	20	9.14
Plant, Property, & Equipment, net	7.01	12	15	30	20	5.63	1.58
Total Noncurrent Assets	192	57	60	94	40	57	18
Long-Term Investments	144	0.00	-	-	-	31	17
Intangible Assets	24	26	29	45	0.00	-	-
Other Noncurrent Operating Assets	24	31	31	49	40	26	1.09
Total Liabilities & Shareholders' Equity	919	546	623	1,013	704	632	465
Total Liabilities	2,377	1,889	1,868	1,878	596	156	88
Total Current Liabilities	154	144	121	135	96	60	33
Accounts Payable	9.62	11	12	12	8.95	8.85	14
Accrued Expenses	67	66	67	81	46	26	12
Current Deferred Revenue	15	6.10	8.16	0.00	-	-	-
Current Employee Benefit Liabilities	58	57	31	37	30	13	4.05
Other Current Liabilities	4.51	4.13	3.68	4.94	9.35	12	3.01
Total Noncurrent Liabilities	2,223	1,745	1,747	1,743	500	95	55
Long-Term Debt	437	446	431	431	92	92	55
Noncurrent Deferred Revenue	17	3.73	-	-	-	-	-
Other Noncurrent Operating Liabilities	1,768	1,295	1,316	1,313	408	3.53	0.50
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.14	0.48	-1.59	1.42	1.63	2.24	0.12
Total Equity & Noncontrolling Interests	-1,458	-1,343	-1,243	-867	106	474	377
Total Preferred & Common Equity	-1,468	-1,354	-1,255	-870	58	408	315
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-1,468	-1,354	-1,255	-870	58	408	315
Common Stock	1,903	1,481	939	842	1,021	848	494
Retained Earnings	-3,096	-2,561	-1,918	-1,437	-889	-440	-179
Treasury Stock	-275	-275	-275	-275	-75	0.00	-
Accumulated Other Comprehensive Income / (Loss)	0.01	0.03	-0.33	-0.13	0.19	0.25	0.00
Noncontrolling Interest	10	11	11	3.41	48	65	62

This table presents BridgeBio Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	882	665	794	849	655	504	626	729
Total Current Assets	695	445	616	783	588	433	553	642
Cash & Equivalents	541	266	408	475	505	302	407	483
Accounts Receivable	115	-	-	-	-	-	-	-
Inventories, net	3.95	-	-	-	-	-	-	-
Prepaid Expenses	35	38	28	28	23	21	25	26
Plant, Property, & Equipment, net	6.70	8.70	9.84	11	12	13	14	16
Total Noncurrent Assets	180	212	168	54	55	58	59	71
Long-Term Investments	128	160	117	-	-	-	-	-
Intangible Assets	28	25	25	26	27	28	28	29
Other Noncurrent Operating Assets	24	27	26	29	28	30	31	42
Total Liabilities & Shareholders' Equity	882	665	794	849	655	504	626	729
Total Liabilities	2,520	1,883	1,876	1,886	1,849	1,853	1,839	1,859
Total Current Liabilities	152	139	134	141	106	110	97	119
Accounts Payable	28	13	18	4.73	4.47	3.87	4.08	10
Accrued Expenses	34	66	67	86	57	68	63	73
Current Deferred Revenue	12	12	15	14	6.59	6.21	6.68	7.52
Current Employee Benefit Liabilities	33	44	29	32	34	29	19	25
Other Current Liabilities	46	4.60	4.62	4.54	4.14	3.78	3.67	4.04
Total Noncurrent Liabilities	2,368	1,744	1,742	1,745	1,743	1,743	1,743	1,740
Long-Term Debt	0.00	436	435	435	442	440	436	1,699
Noncurrent Deferred Revenue	18	19	17	20	-	-	-	-
Other Noncurrent Operating Liabilities	2,351	1,289	1,290	1,290	1,301	1,303	1,307	41
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-0.23	0.65	-0.22	0.53	1.40	0.33	-0.20	-2.39
Total Equity & Noncontrolling Interests	-1,638	-1,219	-1,082	-1,037	-1,195	-1,350	-1,213	-1,128
Total Preferred & Common Equity	-1,648	-1,230	-1,093	-1,050	-1,208	-1,362	-1,226	-1,138
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-1,648	-1,230	-1,093	-1,050	-1,208	-1,362	-1,226	-1,138
Common Stock	1,939	1,876	1,851	1,821	1,460	1,128	1,107	917
Retained Earnings	-3,264	-2,831	-2,669	-2,596	-2,392	-2,215	-2,057	-1,781
Treasury Stock	-323	-275	-275	-275	-275	-275	-275	-275
Accumulated Other Comprehensive Income / (Loss)	0.00	0.01	-0.00	0.00	0.03	0.06	-0.01	-0.35
Noncontrolling Interest	9.96	11	11	12	12	12	12	10

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	2,285.27%	-88.02%	11.38%	745.14%	-79.66%	0.00%	0.00%	0.00%
EBITDA Growth	1.52%	-44.08%	24.30%	-13.49%	-76.55%	-42.06%	-328.56%	0.00%
EBIT Growth	1.58%	-43.29%	23.86%	-14.37%	-76.52%	-42.51%	-328.56%	0.00%
NOPAT Growth	2.37%	-18.58%	11.17%	-21.53%	-78.22%	-44.96%	-318.76%	0.00%
Net Income Growth	16.82%	-34.79%	17.36%	-16.02%	-75.16%	-70.31%	-286.59%	0.00%
EPS Growth	27.09%	-21.17%	16.41%	-2.63%	-53.23%	-16.98%	-112.00%	0.00%
Operating Cash Flow Growth	1.33%	-25.80%	15.75%	-24.57%	-57.62%	-85.58%	-237.49%	0.00%
Free Cash Flow Firm Growth	120.57%	-30.97%	-166.23%	625.00%	132.19%	-84.78%	0.00%	0.00%
Invested Capital Growth	-36.93%	-1.80%	-4.10%	-213.74%	-4,225.81%	55.94%	0.00%	0.00%
Revenue Q/Q Growth	1.90%	-1.33%	-12.42%	22.41%	-62.41%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-13.64%	-5.62%	3.06%	-2.24%	-10.36%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	-13.43%	-5.54%	2.98%	-2.43%	-10.70%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	-8.93%	-8.62%	6.63%	-7.08%	-11.48%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-21.75%	-4.77%	2.36%	-3.03%	-11.19%	0.00%	0.00%	0.00%
EPS Q/Q Growth	-19.01%	-1.54%	2.69%	0.26%	-12.09%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-15.66%	-6.36%	8.83%	-8.18%	-5.28%	-13.31%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	123.95%	-144.75%	80.97%	-2.43%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-36.85%	-2.72%	-5,495.73%	-1.73%	-1.61%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	98.25%	73.71%	95.58%	95.53%	100.00%	100.00%	0.00%	0.00%
EBITDA Margin	-258.95%	-6,272.23%	-521.57%	-767.35%	-5,714.54%	-658.30%	0.00%	0.00%
Operating Margin	-267.22%	-6,528.75%	-659.65%	-827.12%	-5,751.99%	-656.41%	0.00%	0.00%
EBIT Margin	-261.69%	-6,342.04%	-530.29%	-775.73%	-5,732.19%	-660.42%	0.00%	0.00%
Profit (Net Income) Margin	-244.86%	-7,021.94%	-624.17%	-841.20%	-6,127.87%	-711.50%	0.00%	0.00%
Tax Burden Percent	100.21%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	93.37%	110.72%	117.70%	108.44%	106.90%	107.73%	90.15%	99.94%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	38.81%	50.49%	45.93%	154.80%	-173.15%	-67.64%	-44.90%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-79.24%	-100.91%	-50.34%	-63.02%	-70.82%	-48.85%	0.00%	0.00%
Return on Assets (ROA)	-74.14%	-111.72%	-59.25%	-68.34%	-75.71%	-52.63%	0.00%	0.00%
Return on Common Equity (ROCE)	39.11%	50.91%	46.24%	166.00%	-138.31%	-57.33%	-37.47%	0.00%
Return on Equity Simple (ROE_SIMPLE)	37.02%	48.24%	38.63%	67.38%	-872.95%	-70.65%	-53.81%	0.00%
Net Operating Profit after Tax (NOPAT)	-415	-425	-359	-404	-332	-186	-129	-31
NOPAT Margin	-187.06%	-4,570.13%	-461.75%	-578.98%	-4,026.40%	-459.49%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-65.32%	-543.39%	-52.01%	-39.77%	-34.72%	-23.13%	-20.51%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	40.68%	47.42%	44.14%	-	-	-	-	-
Cost of Revenue to Revenue	1.75%	26.29%	4.42%	4.47%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	130.21%	1,618.73%	184.41%	275.70%	1,766.08%	232.63%	0.00%	0.00%
R&D to Revenue	228.24%	4,898.54%	514.45%	646.94%	4,085.91%	517.62%	0.00%	0.00%
Operating Expenses to Revenue	365.48%	6,602.46%	755.22%	922.65%	5,851.99%	756.41%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-581	-590	-412	-541	-473	-268	-188	-44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-575	-584	-405	-535	-471	-267	-188	-44
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	150.52	10.60	1.11	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	150.52	10.60	1.11	0.00
Price to Revenue (P/Rev)	23.37	754.92	14.67	35.21	1,056.59	106.79	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	21.67	755.64	13.78	29.46	1,000.44	96.49	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	58.26	0.00	0.00	4.44	129.31	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	-0.30	-0.33	-0.35	-0.50	0.87	0.19	0.14	0.00
Long-Term Debt to Equity	-0.30	-0.33	-0.35	-0.50	0.86	0.19	0.14	0.00
Financial Leverage	0.14	0.03	0.23	1.21	-1.71	-1.04	-1.06	0.00
Leverage Ratio	-0.52	-0.45	-0.78	-2.27	2.29	1.29	1.23	0.00
Compound Leverage Factor	-0.49	-0.50	-0.91	-2.46	2.44	1.38	1.11	0.00
Debt to Total Capital	-42.86%	-49.82%	-52.95%	-99.06%	46.53%	16.17%	12.62%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.72%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-42.86%	-49.82%	-52.95%	-99.06%	45.81%	16.17%	12.62%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-1.01%	-1.31%	-1.19%	-1.11%	24.77%	11.89%	14.47%	0.00%
Common Equity to Total Capital	143.87%	151.13%	154.14%	200.17%	28.70%	71.94%	72.91%	0.00%
Debt to EBITDA	-0.76	-0.77	-1.06	-0.81	-0.20	-0.34	-0.29	0.00
Net Debt to EBITDA	0.67	0.01	0.19	0.76	1.09	1.82	2.12	0.00
Long-Term Debt to EBITDA	-0.76	-0.77	-1.06	-0.81	-0.20	-0.34	-0.29	0.00
Debt to NOPAT	-1.05	-1.05	-1.20	-1.07	-0.28	-0.49	-0.42	0.00
Net Debt to NOPAT	0.93	0.01	0.22	1.01	1.55	2.60	3.10	0.00
Long-Term Debt to NOPAT	-1.05	-1.05	-1.20	-1.07	-0.28	-0.49	-0.42	0.00
Altman Z-Score	-4.51	-7.14	-5.18	-2.00	5.74	15.35	1.58	0.00
Noncontrolling Interest Sharing Ratio	-0.79%	-0.83%	-0.69%	-7.23%	20.13%	15.23%	16.56%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	4.67	3.32	4.52	6.58	6.72	9.42	13.67	0.00
Quick Ratio	4.44	3.04	4.03	6.34	6.35	9.09	13.39	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	83	-401	-306	463	64	-198	-107	0.00
Operating Cash Flow to CapEx	-55,812.00%	-40,407.35%	0.00%	-3,759.13%	-5,316.76%	-9,612.85%	-6,273.78%	-8,725.86%
Free Cash Flow to Firm to Interest Expense	0.66	-4.94	-3.81	9.89	1.74	-22.62	-42.13	0.00
Operating Cash Flow to Interest Expense	-4.14	-6.49	-5.22	-10.64	-10.90	-28.93	-53.65	-3,114.46
Operating Cash Flow Less CapEx to Interest Expense	-4.14	-6.51	-5.15	-10.93	-11.11	-29.23	-54.50	-3,150.15
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.02	0.09	0.08	0.01	0.07	0.00	0.00
Accounts Receivable Turnover	68.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	23.57	0.71	3.48	2.77	0.64	11.27	0.00	0.00
Accounts Payable Turnover	0.38	0.22	0.29	0.30	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	5.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	954.05	1,657.35	1,245.83	1,220.71	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-948.73	-1,657.35	-1,245.83	-1,220.71	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	-1,845	-1,348	-1,324	-1,272	-405	-9.37	-21	0.00
Invested Capital Turnover	-0.14	-0.01	-0.06	-0.08	-0.04	-2.65	0.00	0.00
Increase / (Decrease) in Invested Capital	-498	-24	-52	-866	-396	12	-21	0.00
Enterprise Value (EV)	4,809	7,030	1,070	2,053	8,253	3,913	12	0.00
Market Capitalization	5,186	7,023	1,139	2,455	8,716	4,331	349	349
Book Value per Share	($7.77)	($7.78)	($8.39)	($5.91)	$0.47	$3.31	$5.10	$0.00
Tangible Book Value per Share	($7.89)	($7.94)	($8.59)	($6.22)	$0.47	$3.31	$5.10	$0.00
Total Capital	-1,020	-896	-814	-435	202	568	432	0.00
Total Debt	437	446	431	431	94	92	55	0.00
Total Long-Term Debt	437	446	431	431	92	92	55	0.00
Net Debt	-388	-5.09	-79	-406	-513	-485	-399	0.00
Capital Expenditures (CapEx)	0.93	1.31	-5.18	13	7.52	2.64	2.18	0.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-115	-118	-82	-83	-58	-38	-23	0.00
Debt-free Net Working Capital (DFNWC)	566	334	427	754	549	508	413	0.00
Net Working Capital (NWC)	566	334	427	754	547	508	413	0.00
Net Nonoperating Expense (NNE)	128	228	126	183	173	102	41	13
Net Nonoperating Obligations (NNO)	-388	-5.09	-79	-406	-513	-485	-399	0.00
Total Depreciation and Amortization (D&A)	6.08	6.49	6.77	5.84	1.46	0.86	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	-51.80%	-1,266.13%	-106.15%	-119.13%	-708.68%	-93.09%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	255.20%	3,587.54%	550.46%	1,081.23%	6,650.92%	1,253.05%	0.00%	0.00%
Net Working Capital to Revenue	255.20%	3,587.54%	550.46%	1,081.23%	6,633.24%	1,253.05%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.88)	($3.95)	($3.26)	($3.90)	($3.80)	($2.48)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	186.08M	162.79M	147.47M	147.61M	148.96M	123.77M	0.00	0.00
Adjusted Diluted Earnings per Share	($2.88)	($3.95)	($3.26)	($3.90)	($3.80)	($2.48)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	186.08M	162.79M	147.47M	147.61M	148.96M	123.77M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($3.90)	($3.80)	($2.48)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	190.19M	175.83M	151.37M	144.36M	118.00M	105.10M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-404	-420	-328	-404	-332	-186	-129	-31
Normalized NOPAT Margin	-182.13%	-4,510.49%	-422.30%	-578.98%	-4,026.40%	-459.49%	0.00%	0.00%
Pre Tax Income Margin	-244.34%	-7,021.94%	-624.17%	-841.20%	-6,127.87%	-711.50%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.61	-7.26	-5.12	-11.56	-12.90	-30.56	-73.80	-3,373.69
NOPAT to Interest Expense	-3.30	-5.23	-4.46	-8.63	-9.06	-21.26	-50.48	-2,361.58
EBIT Less CapEx to Interest Expense	-4.62	-7.27	-5.05	-11.84	-13.11	-30.86	-74.65	-3,409.38
NOPAT Less CapEx to Interest Expense	-3.30	-5.25	-4.39	-8.91	-9.27	-21.56	-51.33	-2,397.28
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	-0.99%	-19.06%	-26.10%	-2.63%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-34.10%	-15.83%	-19.06%	-26.10%	-2.63%

This table displays calculated financial ratios and metrics derived from BridgeBio Pharma's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-44.76%	237.08%	-33.22%	32.11%	11,461.88%	-6.68%	1,110.36%	-97.77%	7.79%	-85.49%	-85.58%
EBITDA Growth	-930.48%	-44.78%	-16.78%	-22.11%	109.13%	-25.23%	-33.18%	-871.40%	30.24%	9.42%	19.20%
EBIT Growth	-1,078.43%	-44.18%	-16.55%	-21.81%	107.75%	-24.84%	-32.73%	-953.03%	30.06%	9.22%	18.24%
NOPAT Growth	-30,529.15%	-27.40%	-21.60%	-20.15%	100.27%	-37.28%	-22.13%	-82.22%	27.36%	21.97%	13.63%
Net Income Growth	-369.05%	-56.98%	8.49%	52.99%	74.67%	-21.17%	-28.03%	-6,179.91%	29.11%	7.69%	12.93%
EPS Growth	-340.00%	-47.42%	20.37%	60.20%	78.26%	-6.59%	-16.13%	-1,300.00%	31.85%	9.00%	12.26%
Operating Cash Flow Growth	9.25%	-56.49%	-24.33%	165.90%	-52.12%	-33.86%	-7.45%	-272.22%	10.16%	30.36%	-11.19%
Free Cash Flow Firm Growth	745.11%	438.23%	-108.30%	-107.24%	-141.29%	-161.69%	189.45%	190.93%	48.50%	-105.11%	-276.39%
Invested Capital Growth	-105.66%	-36.93%	-2.78%	-2.89%	13.34%	-1.80%	-5,445.64%	-3,397.34%	-1.32%	-4.10%	98.11%
Revenue Q/Q Growth	1,882.88%	115.30%	26.01%	-98.97%	11,998.57%	-57.35%	149.30%	-10.13%	-2.35%	453.25%	-99.54%
EBITDA Q/Q Growth	57.47%	-18.37%	-7.91%	-1,628.60%	107.41%	4.51%	-12.83%	-14.27%	-1.72%	-1.55%	-753.54%
EBIT Q/Q Growth	57.16%	-18.14%	-7.82%	-1,892.91%	106.31%	4.50%	-12.69%	-14.09%	-1.68%	-1.54%	-824.22%
NOPAT Q/Q Growth	53.82%	-17.88%	-9.24%	-51,277.55%	100.19%	-12.51%	-7.94%	-15.80%	2.37%	-0.09%	-61.04%
Net Income Q/Q Growth	36.57%	-62.79%	-117.43%	-108.92%	78.77%	5.10%	-11.69%	-12.59%	-1.54%	-0.27%	-5,378.43%
EPS Q/Q Growth	38.46%	-66.28%	-120.51%	-95.00%	79.38%	10.19%	-10.20%	-6.52%	-1.10%	2.15%	-1,228.57%
Operating Cash Flow Q/Q Growth	-2.00%	-8.17%	-341.71%	134.03%	-75.88%	14.05%	-28.12%	21.46%	-54.78%	31.01%	-343.84%
Free Cash Flow Firm Q/Q Growth	227.76%	447.01%	-15.19%	50.76%	-71.85%	-108.52%	0.41%	1,741.37%	-86.38%	97.09%	-2.07%
Invested Capital Q/Q Growth	-25.05%	-36.85%	0.18%	-20.40%	16.75%	-2.72%	0.07%	-1.41%	2.20%	-5,495.73%	36.98%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	97.74%	64.57%	78.11%	72.42%	99.72%	65.73%	85.38%	63.50%	64.35%	-6.68%	-118.64%
EBITDA Margin	-81.33%	-3,791.84%	-6,896.60%	-8,053.37%	5.41%	-8,828.25%	-3,943.68%	-8,713.35%	-6,852.74%	-6,578.18%	-35,840.24%
Operating Margin	-89.49%	-3,842.69%	-7,018.67%	-8,096.82%	0.16%	-10,167.11%	-3,854.61%	-8,903.05%	-6,909.26%	-6,910.80%	-38,200.00%
EBIT Margin	-82.43%	-3,815.08%	-6,952.89%	-8,125.97%	4.65%	-8,919.08%	-3,983.74%	-8,813.10%	-6,942.17%	-6,666.95%	-36,326.92%
Profit (Net Income) Margin	-145.42%	-4,545.89%	-6,012.23%	-3,484.50%	-17.13%	-9,760.92%	-4,387.39%	-9,792.99%	-7,816.65%	-7,517.11%	-41,477.22%
Tax Burden Percent	100.00%	100.43%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	176.42%	118.64%	86.47%	42.88%	-368.00%	109.44%	110.13%	111.12%	112.60%	112.75%	114.18%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	50.59%	38.81%	37.00%	37.96%	48.58%	50.49%	53.65%	49.41%	37.80%	45.93%	53.19%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-12.14%	-1,155.17%	-2,294.11%	-2,743.52%	1.38%	-141.91%	-54.29%	-73.23%	-750.56%	-632.92%	-4,265.33%
Return on Assets (ROA)	-21.41%	-1,376.45%	-1,983.74%	-1,176.45%	-5.08%	-155.30%	-59.79%	-81.38%	-845.10%	-713.63%	-4,870.06%
Return on Common Equity (ROCE)	51.02%	39.11%	37.39%	38.32%	49.12%	50.91%	54.16%	49.89%	38.01%	46.24%	53.64%
Return on Equity Simple (ROE_SIMPLE)	41.06%	0.00%	36.29%	42.23%	52.09%	0.00%	51.63%	42.89%	34.76%	0.00%	43.60%
Net Operating Profit after Tax (NOPAT)	-73	-158	-134	-123	0.24	-124	-110	-102	-88	-90	-90
NOPAT Margin	-62.64%	-2,689.88%	-4,913.07%	-5,667.77%	0.11%	-7,116.97%	-2,698.23%	-6,232.13%	-4,836.48%	-4,837.56%	-26,740.00%
Net Nonoperating Expense Percent (NNEP)	-25.61%	-55.60%	-24.20%	40.81%	-43.82%	-109.91%	13.98%	11.52%	-34.21%	-20.67%	16.81%
Return On Investment Capital (ROIC_SIMPLE)	4.46%	15.51%	-	-	-	13.85%	-	-	-	11.14%	-
Cost of Revenue to Revenue	2.26%	35.43%	21.89%	27.58%	0.28%	34.27%	14.62%	36.50%	35.65%	106.68%	218.64%
SG&A Expenses to Revenue	91.20%	1,611.39%	2,519.00%	2,745.53%	31.17%	2,726.82%	874.53%	2,201.22%	1,703.61%	1,703.85%	9,227.22%
R&D to Revenue	95.54%	2,216.08%	4,408.64%	5,290.36%	66.77%	7,462.81%	3,058.81%	6,550.15%	5,085.49%	4,861.07%	27,370.12%
Operating Expenses to Revenue	187.22%	3,907.26%	7,096.78%	8,169.23%	99.55%	10,232.84%	3,939.99%	8,966.54%	6,973.60%	6,976.20%	38,081.36%
Earnings before Interest and Taxes (EBIT)	-96	-224	-190	-176	9.83	-156	-163	-145	-127	-125	-123
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-95	-223	-188	-175	11	-154	-161	-143	-125	-123	-121
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	51.60	23.37	21.98	21.63	24.61	754.92	454.43	486.45	32.27	14.67	16.62
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	46.43	21.67	21.44	20.45	24.28	755.64	443.36	495.11	31.38	13.78	29.19
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	8.49	58.26	0.00	0.00	0.00	0.00	4.66	3.11	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	-0.30	-0.36	-0.40	-0.42	-0.33	-0.37	-0.33	-0.36	-0.35	-1.50
Long-Term Debt to Equity	0.00	-0.30	-0.36	-0.40	-0.42	-0.33	-0.37	-0.33	-0.36	-0.35	-1.50
Financial Leverage	0.28	0.14	0.10	0.10	0.07	0.03	-0.43	-0.43	0.14	0.23	-0.32
Leverage Ratio	-0.65	-0.52	-0.55	-0.53	-0.66	-0.45	-0.60	-0.58	-0.64	-0.78	-0.81
Compound Leverage Factor	-1.14	-0.62	-0.47	-0.23	2.41	-0.49	-0.66	-0.64	-0.72	-0.87	-0.92
Debt to Total Capital	0.00%	-42.86%	-55.77%	-67.34%	-72.20%	-49.82%	-58.74%	-48.45%	-56.02%	-52.95%	298.90%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	-42.86%	-55.77%	-67.34%	-72.20%	-49.82%	-58.74%	-48.45%	-56.02%	-52.95%	298.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.59%	-1.01%	-1.47%	-1.68%	-2.10%	-1.31%	-1.84%	-1.36%	-1.55%	-1.19%	1.42%
Common Equity to Total Capital	100.59%	143.87%	157.24%	169.01%	174.30%	151.13%	160.57%	149.81%	157.57%	154.14%	-200.31%
Debt to EBITDA	0.00	-0.76	-0.86	-0.91	-0.97	-0.77	-0.80	-0.86	-1.24	-1.06	-4.07
Net Debt to EBITDA	0.00	0.67	0.26	0.56	0.19	0.01	0.21	-0.07	0.23	0.19	-2.65
Long-Term Debt to EBITDA	0.00	-0.76	-0.86	-0.91	-0.97	-0.77	-0.80	-0.86	-1.24	-1.06	-4.07
Debt to NOPAT	0.00	-1.05	-1.14	-1.22	-1.29	-1.05	-1.13	-1.19	-1.34	-1.20	-4.42
Net Debt to NOPAT	0.00	0.93	0.34	0.75	0.25	0.01	0.30	-0.10	0.25	0.22	-2.88
Long-Term Debt to NOPAT	0.00	-1.05	-1.14	-1.22	-1.29	-1.05	-1.13	-1.19	-1.34	-1.20	-4.42
Altman Z-Score	-3.09	-3.23	-4.50	-2.92	-1.37	-4.52	-3.65	-5.43	-3.45	-3.66	-2.52
Noncontrolling Interest Sharing Ratio	-0.84%	-0.79%	-1.05%	-0.95%	-1.10%	-0.83%	-0.94%	-0.97%	-0.55%	-0.69%	-0.83%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.57	4.67	3.19	4.59	5.54	3.32	5.54	3.93	5.72	4.52	5.39
Quick Ratio	4.31	4.44	1.92	3.34	5.34	3.04	5.17	3.56	5.20	4.03	5.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,112	339	-98	-85	-172	-100	1,178	1,173	-71	-38	-1,317
Operating Cash Flow to CapEx	0.00%	-415,587.23%	-131,800.00%	138,338.89%	-31,588.06%	-28,694.02%	-33,695.13%	-26,484.35%	-1,202,683.33%	-11,640.82%	-17,808.04%
Free Cash Flow to Firm to Interest Expense	17.58	11.38	-4.24	-3.70	-3.44	-4.95	58.01	56.96	-3.55	-1.92	-66.42
Operating Cash Flow to Interest Expense	-3.15	-6.55	-7.83	3.26	-4.39	-6.16	-7.15	-5.50	-7.17	-4.66	-6.82
Operating Cash Flow Less CapEx to Interest Expense	-3.15	-6.55	-7.84	3.25	-4.40	-6.18	-7.17	-5.53	-7.17	-4.70	-6.86
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.15	0.30	0.33	0.34	0.30	0.02	0.01	0.01	0.11	0.09	0.12
Accounts Receivable Turnover	0.00	68.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	14.07	23.57	20.63	19.15	17.50	0.71	0.67	0.38	5.06	3.48	4.09
Accounts Payable Turnover	0.37	0.38	0.27	0.22	0.54	0.22	0.53	0.63	0.58	0.29	0.41
Days Sales Outstanding (DSO)	0.00	5.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	994.45	954.05	1,360.74	1,678.51	671.43	1,657.35	694.76	580.25	633.63	1,245.83	889.57
Cash Conversion Cycle (CCC)	-994.45	-948.73	-1,360.74	-1,678.51	-671.43	-1,657.35	-694.76	-580.25	-633.63	-1,245.83	-889.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-2,307	-1,845	-1,348	-1,351	-1,122	-1,348	-1,312	-1,313	-1,295	-1,324	-24
Invested Capital Turnover	-0.07	-0.14	-0.16	-0.16	-0.18	-0.01	-0.01	-0.01	-0.06	-0.06	-0.14
Increase / (Decrease) in Invested Capital	-1,185	-498	-36	-38	173	-24	-1,288	-1,275	-17	-52	1,226
Enterprise Value (EV)	5,916	4,809	4,669	4,482	5,307	7,030	4,180	2,810	2,441	1,070	2,588
Market Capitalization	6,575	5,186	4,787	4,740	5,379	7,023	4,284	2,761	2,510	1,139	1,474
Book Value per Share	($8.67)	($7.77)	($6.54)	($5.84)	($5.87)	($7.78)	($7.43)	($8.49)	($8.10)	($8.39)	($7.68)
Tangible Book Value per Share	($8.81)	($7.89)	($6.67)	($5.97)	($6.02)	($7.94)	($7.60)	($8.66)	($8.28)	($8.59)	($7.88)
Total Capital	-1,639	-1,020	-782	-647	-602	-896	-752	-909	-778	-814	568
Total Debt	0.00	437	436	435	435	446	442	440	436	431	1,699
Total Long-Term Debt	0.00	437	436	435	435	446	442	440	436	431	1,699
Net Debt	-669	-388	-130	-269	-85	-5.09	-118	37	-81	-79	1,107
Capital Expenditures (CapEx)	0.00	0.05	0.14	0.05	0.70	0.44	0.43	0.43	0.01	0.80	0.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.47	-115	-100	-105	122	-118	-78	-81	-61	-82	-69
Debt-free Net Working Capital (DFNWC)	543	566	305	482	642	334	482	323	456	427	523
Net Working Capital (NWC)	543	566	305	482	642	334	482	323	456	427	523
Net Nonoperating Expense (NNE)	97	109	30	-47	36	46	69	58	54	50	50
Net Nonoperating Obligations (NNO)	-669	-388	-130	-269	-85	-5.09	-118	37	-81	-79	1,107
Total Depreciation and Amortization (D&A)	1.28	1.37	1.54	1.57	1.60	1.59	1.64	1.64	1.63	1.66	1.65
Debt-free, Cash-free Net Working Capital to Revenue	1.94%	-51.80%	-46.09%	-48.06%	55.87%	-1,266.13%	-830.63%	-1,426.61%	-78.03%	-106.15%	-77.77%
Debt-free Net Working Capital to Revenue	426.22%	255.20%	140.23%	219.91%	293.67%	3,587.54%	5,108.24%	5,687.47%	586.41%	550.46%	589.90%
Net Working Capital to Revenue	426.22%	255.20%	140.23%	219.91%	293.67%	3,587.54%	5,108.24%	5,687.47%	586.41%	550.46%	589.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.88)	($1.43)	($0.86)	($0.39)	($0.20)	($0.97)	($1.08)	($0.98)	($0.92)	($0.91)	($0.93)
Adjusted Weighted Average Basic Shares Outstanding	190.15M	186.08M	188.51M	187.59M	178.71M	162.79M	163.31M	160.54M	152.65M	147.47M	147.94M
Adjusted Diluted Earnings per Share	($0.88)	($1.43)	($0.86)	($0.39)	($0.20)	($0.97)	($1.08)	($0.98)	($0.92)	($0.91)	($0.93)
Adjusted Weighted Average Diluted Shares Outstanding	190.15M	186.08M	188.51M	187.59M	178.71M	162.79M	163.31M	160.54M	152.65M	147.47M	147.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	189.88M	190.19M	188.99M	188.03M	187.13M	175.83M	173.97M	162.47M	160.50M	151.37M	149.48M
Normalized Net Operating Profit after Tax (NOPAT)	-73	-155	-131	-121	2.62	-124	-110	-100	-86	-85	-87
Normalized NOPAT Margin	-62.30%	-2,634.03%	-4,794.67%	-5,574.43%	1.24%	-7,086.73%	-2,693.57%	-6,081.51%	-4,707.33%	-4,549.66%	-25,701.18%
Pre Tax Income Margin	-145.42%	-4,526.28%	-6,012.23%	-3,484.50%	-17.13%	-9,760.92%	-4,387.39%	-9,792.99%	-7,816.65%	-7,517.11%	-41,477.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.52	-7.53	-8.24	-7.68	0.20	-7.68	-8.03	-7.02	-6.30	-6.24	-6.19
NOPAT to Interest Expense	-1.15	-5.31	-5.82	-5.36	0.00	-6.13	-5.44	-4.97	-4.39	-4.53	-4.56
EBIT Less CapEx to Interest Expense	-1.52	-7.53	-8.24	-7.68	0.18	-7.70	-8.05	-7.04	-6.30	-6.28	-6.23
NOPAT Less CapEx to Interest Expense	-1.15	-5.31	-5.83	-5.36	-0.01	-6.15	-5.46	-4.99	-4.39	-4.57	-4.60
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About BridgeBio Pharma's Financials

When does BridgeBio Pharma's fiscal year end?

According to the most recent income statement we have on file, BridgeBio Pharma's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has BridgeBio Pharma's net income changed over the last 7 years?

BridgeBio Pharma's net income appears to be on an upward trend, with a most recent value of -$543.35 million in 2024, rising from -$43.83 million in 2017. The previous period was -$653.25 million in 2023. View BridgeBio Pharma's forecast to see where analysts expect BridgeBio Pharma to go next.

What is BridgeBio Pharma's operating income?

BridgeBio Pharma's total operating income in 2024 was -$592.97 million, based on the following breakdown:

Total Gross Profit: $218.02 million
Total Operating Expenses: $811.00 million

How has BridgeBio Pharma revenue changed over the last 7 years?

Over the last 7 years, BridgeBio Pharma's total revenue changed from $0.00 in 2017 to $221.90 million in 2024, a change of 22,190,200,000.0%.

How much debt does BridgeBio Pharma have?

BridgeBio Pharma's total liabilities were at $2.38 billion at the end of 2024, a 25.8% increase from 2023, and a 2,614.1% increase since 2018.

How much cash does BridgeBio Pharma have?

In the past 6 years, BridgeBio Pharma's cash and equivalents has ranged from $356.08 million in 2020 to $681.10 million in 2024, and is currently $681.10 million as of their latest financial filing in 2024.

How has BridgeBio Pharma's book value per share changed over the last 7 years?

Over the last 7 years, BridgeBio Pharma's book value per share changed from 0.00 in 2017 to -7.77 in 2024, a change of -776.7%.

Related Companies

This page (NASDAQ:BBIO) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Financials

Frequently Asked Questions About BridgeBio Pharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Financials

Annual Income Statements for BridgeBio Pharma

Quarterly Income Statements for BridgeBio Pharma

Annual Cash Flow Statements for BridgeBio Pharma

Quarterly Cash Flow Statements for BridgeBio Pharma

Annual Balance Sheets for BridgeBio Pharma

Quarterly Balance Sheets for BridgeBio Pharma

Annual Metrics And Ratios for BridgeBio Pharma

Quarterly Metrics And Ratios for BridgeBio Pharma

Frequently Asked Questions About BridgeBio Pharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools